1
Country: USA | Funding: $3.4B
Genetix Biotherapeutics (formerly Bluebird Bio) develops gene therapies for rare genetic diseases using patient's own blood stem cells. The cells are harvested, modified outside the body to add working copies of the affected gene and then reintroduced into the patient, restoring the function of the affected gene. The company specializes in the treatment of sickle cell anemia, beta thalassemia and cerebral adrenoleukodystrophy (CALD). Its unique, single-dose treatments are FDA approved and address the underlying cause of the disease and can provide significant, long-term benefits to patients. Acquired by The Carlyle Group
Genetix Biotherapeutics (formerly Bluebird Bio) develops gene therapies for rare genetic diseases using patient's own blood stem cells. The cells are harvested, modified outside the body to add working copies of the affected gene and then reintroduced into the patient, restoring the function of the affected gene. The company specializes in the treatment of sickle cell anemia, beta thalassemia and cerebral adrenoleukodystrophy (CALD). Its unique, single-dose treatments are FDA approved and address the underlying cause of the disease and can provide significant, long-term benefits to patients. Acquired by The Carlyle Group
2
Country: USA | Funding: $1.3B
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
3
Country: USA | Funding: $1.2B
ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.
ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.
4
Country: USA | Funding: $620M
Century Therapeutics is harnessing the power of adult stem cells to develop curative therapies for cancer. It develops iPSC-derived, allogeneic immune cell therapy products for cancer
Century Therapeutics is harnessing the power of adult stem cells to develop curative therapies for cancer. It develops iPSC-derived, allogeneic immune cell therapy products for cancer
5
Country: USA | Funding: $445M
Rubius is developing a new class of drugs, Red-Cell Therapeutics. Rubius is using advanced cellular therapies that harness the unique, inherent properties of red cells and marry them to the creative power of genetic engineering.
Rubius is developing a new class of drugs, Red-Cell Therapeutics. Rubius is using advanced cellular therapies that harness the unique, inherent properties of red cells and marry them to the creative power of genetic engineering.
6
Country: USA | Funding: $405.9M
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology. Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients.
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology. Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients.
7
Country: USA | Funding: $400M
Celgene spinout that aims is to develop cells from placentas against blood cancers and is founded on the use of stem cells from placentas. The goal is to create therapies across autoimmune and degenerative disease, immuno-oncology, and functional regeneration.
Celgene spinout that aims is to develop cells from placentas against blood cancers and is founded on the use of stem cells from placentas. The goal is to create therapies across autoimmune and degenerative disease, immuno-oncology, and functional regeneration.
8
Country: USA | Funding: $272M
Aspen Neuroscience is a private biotechnology company that uses innovative genomic approaches combined with stem cell biology.
Aspen Neuroscience is a private biotechnology company that uses innovative genomic approaches combined with stem cell biology.
9
Country: UK | Funding: $166.4M
We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
10
Country: USA | Funding: $135.5M
QurAlis is specifically focused on discovering & developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
QurAlis is specifically focused on discovering & developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
11
Country: USA | Funding: $129.6M
Cellular Dynamics International (CDI), a FUJIFILM company, is a leading developer and manufacturer of human cells used in drug discovery, toxicity testing, stem cell banking, and cell therapy development. The Company partners with innovators from around the world to combine biologically relevant human cells with the newest technologies to drive advancements in medicine and healthier living.
Cellular Dynamics International (CDI), a FUJIFILM company, is a leading developer and manufacturer of human cells used in drug discovery, toxicity testing, stem cell banking, and cell therapy development. The Company partners with innovators from around the world to combine biologically relevant human cells with the newest technologies to drive advancements in medicine and healthier living.
12
Country: USA | Funding: $122.5M
Cellino is on a mission to make personalized, autologous stem cell therapies accessible for patients. Cellino’s platform combines label-free imaging and high-speed laser editing with machine learning to automate cell reprogramming
Cellino is on a mission to make personalized, autologous stem cell therapies accessible for patients. Cellino’s platform combines label-free imaging and high-speed laser editing with machine learning to automate cell reprogramming
13
Country: Israel | Funding: $63.1M
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
14
Country: UK | Funding: $48.9M
Mogrify transforms cell therapy by the systematic discovery of novel cell conversions
Mogrify transforms cell therapy by the systematic discovery of novel cell conversions
15
Country: USA | Funding: $40M
Regenexx focuses on developing breakthrough non-surgical options for people suffering from various orthopedic disorders. We have developed a patent-pending procedure that uses your own stem cells and blood growth factors to regenerate bone and cartilage.
Regenexx focuses on developing breakthrough non-surgical options for people suffering from various orthopedic disorders. We have developed a patent-pending procedure that uses your own stem cells and blood growth factors to regenerate bone and cartilage.
16
Country: USA | Funding: $3.7M
Creative Medical Technology Holdings is a clinical-stage biotechnology company focused on treating erectile dysfunction and stroke using stem cell treatments.
Creative Medical Technology Holdings is a clinical-stage biotechnology company focused on treating erectile dysfunction and stroke using stem cell treatments.
17
Country: USA | Funding: $20.4M
Curi Bio is integrating human iPSC-derived cells, tissue-specific biosystems, and AI-enabled data analytics of new therapeutics.
Curi Bio is integrating human iPSC-derived cells, tissue-specific biosystems, and AI-enabled data analytics of new therapeutics.
18
Country: USA | Funding: $20.2M
Tolerance Bio is a biopharmaceutical company focused on manipulating immune tolerance via the thymus.
Tolerance Bio is a biopharmaceutical company focused on manipulating immune tolerance via the thymus.
19
Country: Ireland | Funding: €13.4M
Developing first in class regenerative gene therapies. Proprietary OmniSomes technology uses bioengineered stem cell extracellular vesicles (exosomes) as novel delivery vehicles for RNA based advanced therapeutics with regenerative medicine properties.
Developing first in class regenerative gene therapies. Proprietary OmniSomes technology uses bioengineered stem cell extracellular vesicles (exosomes) as novel delivery vehicles for RNA based advanced therapeutics with regenerative medicine properties.
20
Country: Canada | Funding: CA$14.4M
Acorn Biolabs wants consumers to pay them to store genetic material in a bet that the increasing advances in targeted genetic therapies will yield better healthcare results down the line.
Acorn Biolabs wants consumers to pay them to store genetic material in a bet that the increasing advances in targeted genetic therapies will yield better healthcare results down the line.
21
Country: UK | Funding: £1.5M
Cell Guidance Systems is a biotechnology company developing research tools for stem cell technology.
Cell Guidance Systems is a biotechnology company developing research tools for stem cell technology.
22
Country: Switzerland
Research and development in Stem Cell and Regenerative medicine.
Research and development in Stem Cell and Regenerative medicine.
23
Country: Netherlands
Glycostem is a clinical-stage company, harvesting the power of allogeneic cells like Natural Killer (NK) cells or antigen presenting cell in the field of cellular cancer immunotherapy.
Glycostem is a clinical-stage company, harvesting the power of allogeneic cells like Natural Killer (NK) cells or antigen presenting cell in the field of cellular cancer immunotherapy.
24
Country: India
Advancells is a research oriented company focused on therapeutic applications of Regenerative Medicine. One of the pioneers Stem Cell Company in India, we are passionate about the almost limitless potential of Human Stem Cells in providing a natural cure for any ailment that our body suffers from.
Advancells is a research oriented company focused on therapeutic applications of Regenerative Medicine. One of the pioneers Stem Cell Company in India, we are passionate about the almost limitless potential of Human Stem Cells in providing a natural cure for any ailment that our body suffers from.
